OOIR: Observatory of International Research

Papers

(The H4-Index of Leukemia is 51. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
FBXO21 mediated degradation of p85α regulates proliferation and survival of acute myeloid leukemia	1976
A prognostic survival nomogram for persons with extra-nodal natural killer-/T-cell lymphoma	1719
The evolution of preclinical models for myelodysplastic neoplasms	169
Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children’s Oncology Group Report	159
Response to: Ruxolitinib withdrawal due to the COVID-19	148
Does older age justify chlorambucil control arms for chronic lymphocytic leukemia clinical trials: a SEER-Medicare analysis	126
Retraction Note: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide	125
Hal E. Broxmeyer PhD: Experimental haematologist and umbilical cord blood cell transplant pioneer (27 November, 1944–8 December, 2021)	116
Clonal hematopoiesis and its impact on the aging osteo-hematopoietic niche	116
Emil J. Freireich: Legend in Cancer Research (March 16, 1927 to February 1, 2021)	106
Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia	104
Identification of therapeutic targets of the hijacked super-enhancer complex in EVI1-rearranged leukemia	103
DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML	95
PDP1 is a key metabolic gatekeeper and modulator of drug resistance in FLT3-ITD-positive acute myeloid leukemia	88
Changing causes of death in persons with haematological cancers 1975–2016	86
Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients	82
MCL1 as a therapeutic vulnerability in Burkitt lymphoma	80
Daniel Catovsky (1937–2022)	73
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies	72
Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease	70
Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis	68
Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution	67
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial	67
Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study	64
Role of MBD3-SOX2 axis in residual myeloma following pomalidomide	64

External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy	63
Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach	63
Functional precision oncology for follicular lymphoma with patient-derived xenograft in avian embryos	62
Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia	61
Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia	61
ACOX1-mediated peroxisomal fatty acid oxidation contributes to metabolic reprogramming and survival in chronic lymphocytic leukemia	61
The P2X4 purinergic receptor has emerged as a potent regulator of hematopoietic stem/progenitor cell mobilization and homing—a novel view of P2X4 and P2X7 receptor interaction in orchestrating stem ce	60
Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis	60
Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm	59
The potential of cell-free DNA to reveal the molecular profiles of Langerhans cell histiocytosis and Erdheim–Chester disease in adults	57
What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?	56
Immunoglobulin superfamily member 8 maintains myeloid leukemia stem cells through inhibition of β-catenin degradation	55
Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis	55
Real-world analysis of teclistamab in 123 RRMM patients from Germany	55
A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure	55
PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia	55
Small-molecule inhibitor targeting the Hsp70-Bim protein–protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance	55
A key role of the WEE1-CDK1 axis in mediating TKI-therapy resistance in FLT3-ITD positive acute myeloid leukemia patients	54
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey	53
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?	53
Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures	53
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries	52
REXO5 promotes genomic integrity through regulating R-loop using its exonuclease activity	51
RUNX1 mutations mitigate quiescence to promote transformation of hematopoietic progenitors in Fanconi anemia	51
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community	51
Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse	51